The development of essential hypertension (EH) and inter-individual differences in response to antihypertensive treatment may partly result from genetic heterogeneity. In this study, we conducted an investigation of the combined effects of 5, 10-methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase (MS) A2756G polymorphisms on baseline blood pressure (BP) and BP response to antihypertensive Benazepril treatment in 823 Chinese hypertensive patients with a fixed daily dosage of 10 mg for 15 consecutive days. When MTHFR C677T and MS A2756G polymorphisms were modelled together with adjustment for important covariates, only MTHFR C677T was associated with baseline systolic BP (SBP) (b (s.e.) ¼ 2.84 (1.10), P ¼ 0.0096) or baseline diastolic BP (DBP) (b (s.e.) ¼ 2.19 (0.65), P ¼ 0.0008). Modelled together with adjustment for important covariates, MTHFR C677T and MS A2756G polymorphisms were both independently associated with increased DBP response (baseline minus post-treatment) to Benazepril treatment (C677T: b (s.e.) ¼ 1.58 (0.76), P ¼ 0.038; A2756G: b (s.e.) ¼ 2.14 (0.89), P ¼ 0.016). Neither polymorphism was associated with SBP response to Benazepril treatment. There were no significant interactions or effect modification between MTHFR C677T and MS A2756G gene polymorphisms in models of baseline SBP, baseline DBP or DBP response to Benazepril treatment. Our results suggest that the effects of MTHFR C677T and MS A2756G gene polymorphisms may have pivotal roles in the aetiology of EH and BP response to Benazepril treatment.
The development of essential hypertension (EH) and inter-individual differences in response to antihypertensive treatment may partly result from genetic heterogeneity. In this study, we conducted an investigation of the combined effects of 5, 10-methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase (MS) A2756G polymorphisms on baseline blood pressure (BP) and BP response to antihypertensive Benazepril treatment in 823 Chinese hypertensive patients with a fixed daily dosage of 10 mg for 15 consecutive days. When MTHFR C677T and MS A2756G polymorphisms were modelled together with adjustment for important covariates, only MTHFR C677T was associated with baseline systolic BP (SBP) (b (s.e.) ¼ 2.84 (1.10), P ¼ 0.0096) or baseline diastolic BP (DBP) (b (s.e.) ¼ 2.19 (0.65), P ¼ 0.0008). Modelled together with adjustment for important covariates, MTHFR C677T and MS A2756G polymorphisms were both independently associated with increased DBP response (baseline minus post-treatment) to Benazepril treatment (C677T: b (s.e.) ¼ 1.58 (0.76), P ¼ 0.038; A2756G: b (s.e.) ¼ 2.14 (0.89), P ¼ 0.016). Neither polymorphism was associated with SBP response to Benazepril treatment. There were no significant interactions or effect modification between MTHFR C677T and MS A2756G gene polymorphisms in models of baseline SBP, baseline DBP or DBP response to Benazepril treatment. Our results suggestIntroduction EH is a complex disorder that results from the interaction of multiple genetic and environmental factors. These lines of evidence strongly hint that gene-gene as well as gene-environment interactions may exist in the causation of EH and interindividual difference in response to antihypertensive treatment. Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, has been widely used in clinical practice to treat all stages of EH by blocking the renin-angiotensin system. A previous study estimated that there was only 50% effectiveness in mild-to-moderate hypertension patients receiving a daily 10 mg oral dose of Benazepril. 1 The significant individual variation in Benazepril efficacy suggests that the interaction of two or more genes could be involved.
5, 10-Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are two major metabolizing enzymes in the homocysteine remethylation pathway. Genetic variations of the MTHFR or MS genes may significantly affect homocysteine metabolism. In 1995, Frosst et al. identified a C-to-T transition (C677T) missense mutation. Individuals homozygous for such a mutation have increased thermolability of MTHFR and decreased specific enzyme activity. A common polymorphism of the MS gene, A-to-G transition (A2756G), was also identified. 3 The mutant is located in the adenosylmethionine-binding domain of the enzyme. The previous studies showed that the effect of MTHFR C677T and MS A2756G polymorphisms alone or in combination was to elevate plasma homocysteine levels.
2,4-6 Elevated plasma homocysteine levels have been found in patients with hypertension and vascular diseases, [7] [8] [9] and were positively correlated with blood pressure (BP) levels. 10, 11 A meta-analysis combining 26 English and Chinese studies of the Caucasian and Asian populations showed sufficient evidence of a significant association between the MTHFR C677T polymorphism and hypertension, which suggested that this polymorphism was an independent risk factor for hypertension. 12 Most recently, a genomewide association study identified the association between SBP or DBP and a common non-functional single-nucleotide polymorphism, rs17367504, in the MTHFR gene (P ¼ 2 Â 10(À13)). 13 In light of these findings, we can postulate that MTHFR C677T and MS A2756G polymorphisms could partially explain the individual variations of baseline BP levels and BP responses to Benazepril treatment.
In this study, we tested the independent and interactive effects of the MTHFR C677T and MS A2756G polymorphisms on baseline BP levels and BP response to Benazepril treatment among Chinese hypertensives.
Materials and methods

Study population
This study was conducted on hypertensive patients from the Huoqiu and Yuexi counties in Anhui Province, China. All study subjects were enrolled from July 2000 to May 2001 in a pharmacogenetic trial of Benazepril. A total of 1298 patients were recruited, among whom were 823 individuals with complete measurement and genotype data who met the following criteria: (1) SBP between 140 and 200 mm Hg, or DBP between 90 and 120 mm Hg; (2) without any antihypertensive therapy 2 weeks before this study; (3) aged 21 to 65 years and (4) was residing in the two counties for at least 2 years. To avoid potentially severe adverse effect, patients with secondary hypertension, pregnancy, hypercalcaemia, chronic cardiovascular disease, chronic cerebrovascular disease, chronic liver, renal diseases or body mass index greater than 33 kg m À2 were excluded. Patients who received any antihypertensive therapy within 2 weeks were also excluded. A detailed description is presented elsewhere. 14 Before the investigation, all participants gave written informed consent and the Institutional Review Boards of Anhui Medical University approved our study protocols.
Benazepril treatment protocol and BP measurements Study subjects without any antihypertensive therapy 2 weeks before this study were treated once daily for 15 consecutive days with a daily dose of 10 mg of Benazepril (Ciba-Geigy, Beijing, China).
On the first day of the study, subjects came to the research centre to receive a physical examination including measurements of both SBP and DBP in a supine position after a 60-min rest period. During the 15-day treatment period, the study subjects kept dairies of daily use of Benazepril and any possible adverse events. On the sixteenth day, subjects returned to the research centre where their BPs were measured again in a supine position after resting for 60 min. Trained nurses made all of the BP measurements at three different time points using a standardized mercury-gravity monometer with appropriately sized cuffs.
Baseline survey
After enrollment, experienced physicians performed a physical examination of all the patients, and trained investigators measured weight and height according to standard methods. A structured baseline questionnaire was administered by trained interviewers to all patients for collecting information including sociodemographic characteristics, occupational types, education, age, gender, cigarette smoking and alcohol consumption.
Blood sampling and DNA extraction Before breakfast and between 0700 and 0900 hours, a forearm venous blood sample was drawn from each subject by venipuncture and was collected into a 10-ml vacutainer (Becton Dickinson, Franklin Lakes, NJ, USA) containing EDTA. DNA was extracted by a method that has been described previously. 15 Detection of the MTHFR C677T and MS A2756G polymorphisms The methods of genotyping MTHFR C677T 2 and MS A2756G 16 were described previously. In brief, the regions that span the MTHFR and MS singlenucleotide polymorphisms were amplified by PCR. The PCR products of MTHFR and MS were digested by HinfI and HaeIII, respectively. The digested PCR fragments of MTHFR and MS were separated electrophoretically on 2 and 3% agarose gels, respectively. The results of agarose gel electrophoresis were visualized by ethidium bromide staining and UV transillumination. Each 96-well plate of genotyped DNA samples contained two random negative controls and 5B10% repeated samples for quality control, whose concordance rate was required to be up to 98% at least. Genotypes were scored independently by two experienced researchers.
Statistical analysis
All data were analysed using SAS for Windows 8.20. (SAS Institute, Cary, NC, USA). Results were expressed as mean±standard deviation (s.d.) for continuous variables, and as counts and proportions for categorical variables. A total of 823 patients were Roles of MTHFR and MS gene polymorphisms in the aetiology of EH and BP response S Jiang et al finally included in the analysis. We tested the independent effects of the MTHFR C677T and MS A2756G gene polymorphisms by using binary variables (heterozygous or homozygous for the mutation) for each polymorphism included simultaneously in linear regression models. The outcomes modelled included baseline SBP, baseline DBP, SBP response (baseline minus post-treatment) and DBP response to Benazepril treatment. We applied false discovery rate analysis to adjust for multiple testing. For outcomes with which we identified the independent effects of either C677T or A2756G, we tested for interaction or effect modification by modelling polymorphisms by using binary variables for each polymorphism plus an interaction term included simultaneously in linear regression models. The results of all models were described with and without adjustment for age, gender, body mass index, current smoking, current alcohol consumption, education, occupation and history of taking antihypertensive medicine. The models of SBP and DBP response were also adjusted for baseline SBP and DBP. Because there were multiple family members from the same nuclear family included in the study, we used generalized estimating equations in all models to accommodate correlations in the outcomes for members of the same family. 17 Results Table 1 presents the sociodemographic and clinical characteristics of the study sample, which consisted of 46.5% men and 53.5% women. The average age and body mass index were 49.2 ± 7.5 years and 25.0±3.5 kg m À2 , respectively. The mean SBP and DBP were 153.0±13.5 and 95.3±7.9 mm Hg, respectively. The frequencies of MS AA, AG and GG genotypes were 81.5, 17.7 and 0.7%, respectively. The frequencies of MTHFR CC, CT and TT genotypes were 26.1, 51.0 and 22.8%, respectively. The distributions of education, occupation, smoking, drinking and other characteristics are shown in Table 1 . The distributions of MTHFR C677T and MS A2756G genotypes did not deviate significantly from Hardy-Weinberg equilibrium (P ¼ 0.525 and 0.489, respectively).
Because the MS GG genotype was very rare (only six patients) in our study population, we combined the AG and GG genotypes into one group. The TT genotype of MTHFR C677T results in elevated homocysteine level, 18 whereas the G allele of MS A2756G is associated with reduced homocysteine level. [4] [5] [6] 19 In the following analysis, we therefore focus on the dichotomized variables (CT/CC) vs TT for MTHFR and (AG/GG) vs AA for MS.
As shown in Table 2 , when MTHFR C677T and MS A2756G polymorphisms were modelled together, only C677T was independently associated with baseline SBP (b (s.e.) ¼ 2.84 (1.10), P ¼ 0.0096) or baseline DBP (b (s.e.) ¼ 2.19 (0.65), P ¼ 0.0008) 
Discussion
In this study, we found that the MTHFR TT genotype (homogenous mutant type) and the MS AA (homogenous wild type) in hypertensive patients were independent predictors of better efficacy of Benazepril treatment for DBP but not for SBP. The combined effects of these genotypes on the efficacy of Benazepril treatment for DBP were additive without interaction. In addition, the MTHFR TT genotype was associated with both higher SBP and DBP at baseline, but the MS AA genotype was not associated with either. The MS AA genotype did not modify the effect of the MTHFR TT genotype on either baseline SBP or DBP. According to previous investigations, both MTHFR and MS are important metabolizing enzymes of homocysteine. C677T and A2756G are two common polymorphisms located in the MTHFR and MS genes, respectively. The T allele of the MTHFR C677T polymorphism increases enzyme thermolability and decreases enzyme bioactivity, resulting in decreased formation of 5-methyltetrahydrofolate. 2 The decrease of the methyl donor hampers the remethylation of homocysteine metabolism and causes higher plasma homocysteine levels. 18, 20 The G allele of the MS A2756G polymorphism increases MS bioactivity and increases the rate of homocysteine conversion to methionine, and increases the plasma folate level. 4, 21 Thus, the T allele of the MTHFR C677T polymorphism and the A allele of the MS A2756G polymorphism may have joint effects on the elevated homocysteine level in plasma. Previous studies that simultaneously investigated the MTHFR and MS polymorphisms showed that those subjects with MTHFR 677TT and MS AA genotypes had severely elevated plasma homocysteine levels. 5, 6 Zhao et al. 22 confirmed that hyper-homocysteinaemia is extremely common in Chinese hypertensive patients, namely, 75% of all the subjects had elevated plasma homocysteine level. The elevated homocysteine levels, as a principal risk factor for both vascular diseases 23, 24 and hypertension, 7, 25 were significantly associated with the BP level. 10, 11 A study that showed individuals to have a decrease in BP level by randomized homocysteine-lowering treatment (folic acid plus pyridoxine) indicated a tight linkage between homocysteine and BP levels. 26 There were lines of evidence indicating that the MTHFR polymorphism is a significant predictor for hypertension risk. 13 Our previous study with a relatively small sample size (n ¼ 444) found that the MTHFR C677T polymorphism modulated baseline DBP and DBP responsiveness to ACE inhibitor in Chinese essential hypertensive patients. 27 In this study we enrolled a larger sample including another independent population and consistently found that baseline SBP and DBP were higher in patients with the MTHFR TT genotype, but there was no effect of the MS AA genotype. This suggests that MTHFR is a more essential metabolizing enzyme than MS in the homocysteine pathway. The potential mechanisms remain to be further elucidated.
The exact biological mechanisms by which the MTHFR C677T and MS A2756G polymorphisms are associated with the response of DBP to Benazepril treatment remain to be elucidated, but are plausible. A previous study found that elevated angiotensin-II level induced endothelial dysfunction in hypertension. 28 Endothelial dysfunction results in a decrease in nitric oxide (NO) 29 and bradykinin, 30 and an increase in endothelin. 31, 32 Benazepril, as an ACE inhibitor, mainly inhibits the bioactivity of the ACE and hinders the formation of angiotensin-II from angiotensin-I, and prevents the degradation of bradykinin. 33 A previous study reported that ACE inhibitor can produce beneficial effects for the cardiovascular system by stimulating the bradykinin-NO pathway, 34 preventing or reversing endothelial dysfunction, and improving renal function in hypertension. 35, 36 Individuals with the MTHFR TT and MS AA genotypes may have severely elevated plasma homocysteine levels, 5, 6 which in turn, induce endothelial dysfunction. 37, 38 Poduri et al.
39
identified that ACE inhibitors provide beneficial therapeutic effects to EH patients by directly decreasing homocysteine levels. So, Benazepril may improve endothelial dysfunction such that a higher plasma homocysteine level is induced, which naturally generates a greater BP response to Benazepril treatment. Accordingly, the antihypertensive effect of Benazepril might be increased by reducing the elevated homocysteine levels among hypertensive patients with both MTHFR TT and MS AA genotypes. One limitation of our study is that we did not measure homocysteine and folic acid in plasma before or after Benazepril treatment. Thus, we do not have direct evidence to evaluate the effect of the MTHFR C677T and MS A2756G gene polymorphisms on plasma homocysteine levels, although previous studies supported this hypothesis. 5, 6 In summary, our study showed an independent effect of the MTHFR C677T polymorphism on baseline DBP and SBP and DBP responses to Benazepril in 823 Chinese hypertensive patients. These results confirm previous reports of the effect of MTHFR C677T on the development of hypertension and suggest that additive effects of genes may have a significant role in the effectiveness of Benazepril treatment.
What is known about topic K The T allele of the MTHFR C677T polymorphism increases enzyme thermolability, decreases enzyme bioactivity and causes elevated plasma homocysteine level. The G allele of the MS A2756G polymorphism increases MS bioactivity and increases the rate of conversion of homocysteine to methionine. K The MTHFR and MS polymorphisms showed that those subjects with MTHFR 677TT and MS AA genotypes have severely elevated plasma homocysteine levels. K The elevated homocysteine levels, as a key risk factor for both vascular diseases and hypertension, are significantly associated with blood pressure level.
What this study adds K In our study we found that baseline SBP and DBP were higher in patients with the MTHFR TT genotype, but there was no effect of the MS AA genotype. K The MTHFR C677T and MS A2756G polymorphisms were associated with the response of DBP to Benazepril treatment.
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